<DOC>
	<DOCNO>NCT02699099</DOCNO>
	<brief_summary>The purpose study assess immunogenicity , safety , reactogenicity SB257049 candidate malaria vaccine co-administered Vitamin A , measles , rubella yellow fever vaccine child age 6 month first vaccination .</brief_summary>
	<brief_title>Immunogenicity Safety Study GSK Biologicals ' Candidate Malaria Vaccine Given 6 , 7.5 9 Months Age Co-administration With Measles , Rubella Yellow Fever ( YF ) Vaccines Followed Booster Malaria Vaccine .</brief_title>
	<detailed_description />
	<mesh_term>Malaria</mesh_term>
	<mesh_term>Rubella</mesh_term>
	<mesh_term>Yellow Fever</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<mesh_term>Vitamins</mesh_term>
	<mesh_term>Vitamin A</mesh_term>
	<mesh_term>Retinol palmitate</mesh_term>
	<criteria>Subjects ' parent ( ) /Legally Acceptable Representative ( ) ( LAR [ ] ) , opinion investigator , comply requirement protocol . A male female 6 month age ( day child become 6 month age day child achieve 7 month age ) time first vaccination . Signed thumbprinted informed consent obtain parent ( ) /LAR ( ) subject . Where parent ( ) /LAR ( ) illiterate , consent form countersign independent witness . Healthy subject establish medical history clinical examination enter study . Previously receive three document dos diphtheria , tetanus , wholecell pertussis , hepatitis B vaccine ( DTPwHepB ) , 3dose course oral polio vaccine , locally recommend , pneumococcal rotavirus vaccine . Child care Use drug vaccine approve indication study vaccine within 30 day precede first dose study vaccine , plan use study period . Any medical condition judgment investigator would make intramuscular injection unsafe . Chronic administration immunosuppressant immunemodifying drug within six month prior first vaccine dose . For corticosteroid , mean prednisone≥ 0.5 mg/kg/day , equivalent . Inhaled topical steroid allow . Planned administration/administration vaccine foreseen study protocol period start seven day first dose SB257049 measles , rubella YF vaccine end 42 day last dose vaccine give 9 month age ( Visit 4 ) , exception oral polio vaccine could give unforseen public health threat . Concurrently participate another clinical study , time study period , subject expose investigational noninvestigational vaccine/product . Previous vaccination measles , YF rubella . Previous administration Vitamin A . Moderate severe malnutrition screening define weight age Zscore &lt; 2 . Any confirmed suspected immunosuppressive immunodeficient condition , base medical history physical examination . Family history congenital hereditary immunodeficiency . History reaction hypersensitivity likely exacerbate component vaccine ( ) . See also Section 1.3 . Major congenital defect serious chronic illness . History neurological disorder seizure . Acute disease and/or fever time enrolment . Fever define temperature ≥ 37.5°C /99.5°F oral , axillary tympanic route , ≥ 38.0°C /100.4°F rectal route . The preferred route record temperature study axillary . Subjects minor illness without fever may , enrol discretion investigator . Administration immunoglobulins and/or blood product within 3 month precede first dose study vaccine plan administration study period . Same sex twin . Maternal death . Previous participation malaria study .</criteria>
	<gender>All</gender>
	<minimum_age>6 Months</minimum_age>
	<maximum_age>6 Months</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>Children</keyword>
	<keyword>Infants</keyword>
	<keyword>SB257049</keyword>
	<keyword>Malaria</keyword>
	<keyword>Immunogenicity</keyword>
	<keyword>Surveillance</keyword>
	<keyword>Efficacy</keyword>
	<keyword>Safety</keyword>
	<keyword>Africa</keyword>
	<keyword>Plasmodium falciparum</keyword>
</DOC>